Targeted Oncology

AVC-203 Achieves Trial Approval from FDA, EMA for R/R B-Cell Lymphoma

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...
Healio

‘Complete eradication’ of B cells drives remission after autoimmune CAR T-cell therapy

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients ...
The Scientist

A Red Blood Cell Protein Turns Dendritic Cells Tolerant

Erythropoietin, the protein that drives red blood cell formation, also induces tolerance in dendritic cells, leading to the ...
Medscape

Epstein-Barr Virus Alters B Cells, Possibly Driving Lupus

Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...

Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...